A9543344 — Hb Yttrium Y-90 Ibritumomab Tiuxetan Tx To 40 Mci
Cite this view
HANK Price Transparency. (n.d.). HB YTTRIUM Y-90 IBRITUMOMAB TIUXETAN TX TO 40 MCI (OTHER A9543344) negotiated rates. PPMan price-transparency data, derived from CMS-required hospital MRFs. Retrieved , from http://ppman.hank.ai/transparency/code/A9543344?code_type=OTHER
“HB YTTRIUM Y-90 IBRITUMOMAB TIUXETAN TX TO 40 MCI (OTHER A9543344) negotiated rates.” HANK Price Transparency, http://ppman.hank.ai/transparency/code/A9543344?code_type=OTHER. Accessed .
“HB YTTRIUM Y-90 IBRITUMOMAB TIUXETAN TX TO 40 MCI (OTHER A9543344) negotiated rates,” HANK Price Transparency, accessed , http://ppman.hank.ai/transparency/code/A9543344?code_type=OTHER.
Source: PPMan price-transparency data, derived from CMS-required hospital machine-readable files (45 CFR 180). See methodology.
Usually $102,358–$132,103 (25th–75th percentile) across 1 hospital · 1 payer.
“Negotiated” is the hospital’s negotiated facility rate for this OTHER A9543344 — the consumer-grade median across the country. It covers the facility charge only; the surgeon’s and anesthesiologist’s fees are billed separately.
Per-month price trends are temporarily unavailable while we rebuild them on quality-filtered rates. The medians, percentiles, and per-hospital rates on this page are the quality-filtered figures.
Hospital rates (per row)
Showing consumer-grade rates only. Flagged / outlier filings (excluded from the medians above) are hidden — tick “Show flagged / outlier rates” to include them.
| Hospital | Payer | Plan | Negotiated rate | Gross | Cash | Observed | Source |
|---|---|---|---|---|---|---|---|
| KAISER PERMANENTE CENTRAL HOSPITAL Both | [Kaiser Foundation Health Plan Of Washington] | [Medicare] | $87,485.72 | $191,069.00 | $152,855.20 | 2026-05-23 | MRF ↗ |
| KAISER PERMANENTE CENTRAL HOSPITAL Both | [Kaiser Foundation Health Plan Of Washington] | [Commercial] | $146,976.00 | $191,069.00 | $152,855.20 | 2026-05-23 | MRF ↗ |